Published in Oncologist on February 21, 2012
Targeted therapies in neuroendocrine tumors (NET): clinical trial challenges and lessons learned. Oncologist (2013) 1.09
Immune Reactivity and Pseudoprogression or Tumor Flare in a Serially Biopsied Neuroendocrine Patient Treated with the Epigenetic Agent RRx-001. Case Rep Oncol (2016) 0.89
Flushing Out Carcinoid Syndrome: Beneficial Effect of the Anticancer Epigenetic Agent RRx-001 in a Patient with a Treatment-Refractory Neuroendocrine Tumor. Case Rep Oncol (2015) 0.82
The use of targeted therapies in pancreatic neuroendocrine tumours: patient assessment, treatment administration, and management of adverse events. Ther Adv Med Oncol (2013) 0.75
Nothing But NET: A Review of Neuroendocrine Tumors and Carcinomas. Neoplasia (2017) 0.75
Cancer statistics, 2010. CA Cancer J Clin (2010) 103.28
One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol (2008) 15.05
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.93
Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med (2011) 11.55
DAXX/ATRX, MEN1, and mTOR pathway genes are frequently altered in pancreatic neuroendocrine tumors. Science (2011) 10.26
Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol (2009) 9.27
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol (2008) 4.66
Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med (1992) 4.33
Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol (2008) 3.85
Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol (2004) 3.43
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol (2009) 3.18
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer (1991) 2.98
Carcinoid tumors. Oncologist (2008) 2.86
Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol (2006) 2.80
First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer (2010) 2.74
Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol (2011) 2.72
Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med (1980) 2.72
Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med (1986) 2.70
Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol (2009) 2.63
Future directions in the treatment of neuroendocrine tumors: consensus report of the National Cancer Institute Neuroendocrine Tumor clinical trials planning meeting. J Clin Oncol (2011) 2.57
Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol (2008) 2.53
Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer (1999) 2.46
Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med (2002) 2.44
A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer (2006) 2.23
Lack of efficacy of streptozocin and doxorubicin in patients with advanced pancreatic endocrine tumors. Am J Clin Oncol (2004) 2.18
Prognostic relevance of a novel TNM classification system for upper gastroenteropancreatic neuroendocrine tumors. Cancer (2008) 2.16
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res (2007) 2.16
Hepatic artery embolization and chemoembolization for treatment of patients with metastatic carcinoid tumors: the M.D. Anderson experience. Cancer J (2003) 2.02
Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med (1973) 2.01
O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res (2009) 2.00
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol (2001) 1.94
Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters. Endocr Relat Cancer (2010) 1.85
Octreotide as an antineoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer (1993) 1.77
Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg (2003) 1.74
Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol (2005) 1.72
Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res (1990) 1.72
Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: variables affecting response rates and survival. Cancer (2005) 1.67
Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging (2003) 1.66
Identification of cancer stem cells in human gastrointestinal carcinoid and neuroendocrine tumors. Gastroenterology (2011) 1.64
Clinical outcome and long-term survival in 118 consecutive patients with neuroendocrine tumours of the pancreas. Br J Surg (2008) 1.50
90Y-edotreotide for metastatic carcinoid refractory to octreotide. J Clin Oncol (2010) 1.49
Laparoscopic radiofrequency ablation of neuroendocrine liver metastases: a 10-year experience evaluating predictors of survival. Surgery (2007) 1.48
Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol (1984) 1.44
Metastatic and locally advanced pancreatic endocrine carcinomas: analysis of factors associated with disease progression. J Clin Oncol (2011) 1.42
Pancreatic endocrine tumors. Semin Oncol (2010) 1.40
Genetics of neuroendocrine and carcinoid tumours. Endocr Relat Cancer (2003) 1.37
Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med (1983) 1.33
Somatostatin receptor-targeted radionuclide therapy of tumors: preclinical and clinical findings. Semin Nucl Med (2002) 1.33
Imaging of gastroenteropancreatic neuroendocrine tumors. World J Clin Oncol (2011) 1.33
90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg (2008) 1.30
Selective hepatic artery embolization for treatment of patients with metastatic carcinoid and pancreatic endocrine tumors. Cancer Control (2006) 1.27
Effect of a long-acting somatostatin analogue (SMS 201-995) in a patient with pancreatic cholera. N Engl J Med (1985) 1.24
Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol (2005) 1.23
Role of somatostatins in gastroenteropancreatic neuroendocrine tumor development and therapy. Gastroenterology (2010) 1.19
Clinical and in vitro studies of imatinib in advanced carcinoid tumors. Clin Cancer Res (2007) 1.14
Receptor-mediated radionuclide therapy with 90Y-DOTATOC in association with amino acid infusion: a phase I study. Eur J Nucl Med Mol Imaging (2002) 1.13
Laparoscopic radiofrequency thermal ablation of neuroendocrine hepatic metastases: long-term follow-up. Surgery (2010) 1.05
Treatment of metastatic islet cell carcinoma with a somatostatin analogue (SMS 201-995). Ann Intern Med (1987) 1.05
Chemotherapy with 5-fluorouracil, cisplatin and streptozocin for neuroendocrine tumours. Br J Cancer (2010) 1.02
Combination therapy with octreotide and alpha-interferon: effect on tumor growth in metastatic endocrine gastroenteropancreatic tumors. Am J Gastroenterol (1999) 1.00
Phase II study of radiopeptide 177Lu-octreotate and capecitabine therapy of progressive disseminated neuroendocrine tumours. Eur J Nucl Med Mol Imaging (2010) 0.98
Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer (1993) 0.98
Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer (1994) 0.97
Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: a prospective single center study. Digestion (2009) 0.96
90Y-DOTA-D-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers (2002) 0.96
Treatment of inoperable glucagonoma with the long-acting somatostatin analogue SMS 201-995. N Engl J Med (1986) 0.95
Hypothalamic hormones a.k.a. hypothalamic releasing factors. J Endocrinol (2005) 0.93
Treatment with (90)Y- and (177)Lu-DOTATOC in patients with metastatic neuroendocrine tumors. Surgery (2006) 0.91
A phase II trial of alpha-interferon and 5-fluorouracil in patients with advanced carcinoid and islet cell tumors. Cancer (1994) 0.91
Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors. J Clin Oncol (1995) 0.86
Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer (2009) 0.85
High-administered activity In-111 octreotide therapy with concomitant radiosensitizing 5FU chemotherapy for treatment of neuroendocrine tumors: preliminary experience. Cancer Biother Radiopharm (2009) 0.83
Remission of symptoms during long term treatment of metastatic pancreatic endocrine tumours with long acting somatostatin analogue. Br Med J (Clin Res Ed) (1986) 0.81
Delivering affordable cancer care in high-income countries. Lancet Oncol (2011) 12.79
Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol (2007) 11.77
Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol (2004) 9.73
Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol (2007) 9.29
Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol (2003) 8.95
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
American Society of Clinical Oncology Statement on minimum standards and exemplary attributes of clinical trial sites. J Clin Oncol (2008) 4.79
In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc (2015) 4.70
Global gene expression profiling of circulating tumor cells. Cancer Res (2005) 3.41
Phase I pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal antibody with agonist activity to tumor necrosis factor-related apoptosis-inducing ligand receptor-1. J Clin Oncol (2007) 3.37
Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol (2008) 3.34
American Society of Clinical Oncology perspective: Raising the bar for clinical trials by defining clinically meaningful outcomes. J Clin Oncol (2014) 3.20
Patients' decision-making process regarding participation in phase I oncology research. J Clin Oncol (2006) 2.72
Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J Clin Oncol (2002) 2.41
Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol (2010) 2.41
Centralization of cancer surgery: implications for patient access to optimal care. J Clin Oncol (2009) 2.40
Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer (2008) 1.89
The continuum of care: a paradigm for the management of metastatic colorectal cancer. Oncologist (2007) 1.89
The culture of faith and hope: patients' justifications for their high estimations of expected therapeutic benefit when enrolling in early phase oncology trials. Cancer (2010) 1.84
Correlates of colorectal cancer screening compliance and stage of adoption among siblings of individuals with early onset colorectal cancer. Health Psychol (2002) 1.84
American Society of Clinical Oncology 2008 clinical practice guideline update: use of chemotherapy and radiation therapy protectants. J Clin Oncol (2008) 1.80
Isolation and characterization of circulating tumor cells in patients with metastatic colorectal cancer. Clin Colorectal Cancer (2006) 1.72
Facilitating informed decisions regarding microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. J Clin Oncol (2010) 1.69
The correlation between patient characteristics and expectations of benefit from Phase I clinical trials. Cancer (2003) 1.65
Predictors of long-term outcomes in older breast cancer survivors: perceptions versus patterns of care. J Clin Oncol (2003) 1.54
Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer (2007) 1.52
Communication between physicians and older women with localized breast cancer: implications for treatment and patient satisfaction. J Clin Oncol (2002) 1.49
The National Cancer Institute-American Society of Clinical Oncology Cancer Trial Accrual Symposium: summary and recommendations. J Oncol Pract (2013) 1.48
Telomerase is frequently activated in tumors with microsatellite instability. Cancer Biol Ther (2004) 1.47
The base excision repair enzyme MED1 mediates DNA damage response to antitumor drugs and is associated with mismatch repair system integrity. Proc Natl Acad Sci U S A (2003) 1.41
UGT1A7 and UGT1A9 polymorphisms predict response and toxicity in colorectal cancer patients treated with capecitabine/irinotecan. Clin Cancer Res (2005) 1.39
Fibroblast activation protein and its relationship to clinical outcome in pancreatic adenocarcinoma. Pancreas (2008) 1.38
Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer (2005) 1.37
Phase II trial of single agent Val-boroPro (Talabostat) inhibiting Fibroblast Activation Protein in patients with metastatic colorectal cancer. Cancer Biol Ther (2007) 1.35
Trends in centralization of cancer surgery. Ann Surg Oncol (2010) 1.35
Expectations of benefit in early-phase clinical trials: implications for assessing the adequacy of informed consent. Med Decis Making (2008) 1.34
Proteomic analyses of pancreatic cyst fluids. Pancreas (2009) 1.29
A randomized trial of generic versus tailored interventions to increase colorectal cancer screening among intermediate risk siblings. Ann Behav Med (2009) 1.26
Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res (2012) 1.21
Phase II and pharmacodynamic study of the farnesyltransferase inhibitor R115777 as initial therapy in patients with metastatic pancreatic adenocarcinoma. J Clin Oncol (2003) 1.17
The American Society of Clinical Oncology's Blueprint for Transforming Clinical and Translational Cancer Research. J Clin Oncol (2012) 1.16
Multiple behavioral risk factors for colorectal cancer and colorectal cancer screening status. Cancer Epidemiol Biomarkers Prev (2007) 1.16
Radiation Therapy Oncology Group 0247: a randomized Phase II study of neoadjuvant capecitabine and irinotecan or capecitabine and oxaliplatin with concurrent radiotherapy for patients with locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2011) 1.13
Understanding how out-of-pocket expenses, treatment value, and patient characteristics influence treatment choices. Oncologist (2010) 1.12
Research participants' high expectations of benefit in early-phase oncology trials: are we asking the right question? J Clin Oncol (2012) 1.11
Understanding intention to undergo colonoscopy among intermediate-risk siblings of colorectal cancer patients: a test of a mediational model. Prev Med (2003) 1.10
Patient and provider characteristics that affect the use of axillary dissection in older women with stage I-II breast carcinoma. Cancer (2002) 1.08
Cost concerns of patients with cancer. J Oncol Pract (2013) 1.07
Using health communication best practices to develop a web-based provider-patient communication aid: the CONNECT study. Patient Educ Couns (2008) 1.05
Ongoing challenge of stage II colon cancer. J Clin Oncol (2011) 1.04
Circulating tumor cells: evolving evidence and future challenges. Oncologist (2009) 1.04
Targeting signal transduction pathways in colorectal cancer--more than skin deep. J Clin Oncol (2005) 1.04
Cancer patients' trade-offs among efficacy, toxicity, and out-of-pocket cost in the curative and noncurative setting. Med Care (2013) 1.04
Phase I trial of preoperative hypofractionated intensity-modulated radiotherapy with incorporated boost and oral capecitabine in locally advanced rectal cancer. Int J Radiat Oncol Biol Phys (2007) 1.03
2002 update of recommendations for the use of chemotherapy and radiotherapy protectants: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol (2002) 1.03
Loss of methylthioadenosine phosphorylase and elevated ornithine decarboxylase is common in pancreatic cancer. Clin Cancer Res (2004) 1.02
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661. Clin Cancer Res (2002) 1.02
Neoadjuvant chemoradiotherapy for adenocarcinoma of the pancreas: analysis of histopathology and outcome. Int J Gastrointest Cancer (2003) 1.01
Gastric Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw (2006) 1.00
Knowledge and attitudes about microsatellite instability testing among high-risk individuals diagnosed with colorectal cancer. Cancer Epidemiol Biomarkers Prev (2007) 1.00
Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma. Int J Radiat Oncol Biol Phys (2007) 1.00
Phase II study of dasatinib (BMS-354825) in patients with metastatic adenocarcinoma of the pancreas. Oncologist (2013) 0.98
Treatment of advanced colorectal carcinoma with oxaliplatin and capecitabine: a phase II trial. Cancer (2004) 0.97
Cancer genetic risk assessment and referral patterns in primary care. Genet Test Mol Biomarkers (2009) 0.96
Cost implications of new treatments for advanced colorectal cancer. Cancer (2009) 0.96
KRAS and colorectal cancer: ethical and pragmatic issues in effecting real-time change in oncology clinical trials and practice. Oncologist (2011) 0.96
End points in advanced colon cancer clinical trials: a review and proposal. J Clin Oncol (2007) 0.95
Use of molecular imaging to predict clinical outcome in patients with rectal cancer after preoperative chemotherapy and radiation. Int J Radiat Oncol Biol Phys (2008) 0.95
Phase I and pharmacokinetic study of once daily oral administration of S-1 in patients with advanced cancer. Clin Cancer Res (2002) 0.94
Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol (2011) 0.94
Pharmacokinetic analysis of irinotecan plus bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol (2009) 0.93
Esophageal cancer. J Natl Compr Canc Netw (2008) 0.93
Esophageal cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2003) 0.92
Comparative effectiveness research to inform medical decisions: the need for common language. J Clin Oncol (2012) 0.92
Phase I assessment of new mechanism-based pharmacodynamic biomarkers for MLN8054, a small-molecule inhibitor of Aurora A kinase. Cancer Res (2010) 0.92
Talking with patients about dying. N Engl J Med (2013) 0.90
Preoperative chemoradiation in the management of adenocarcinoma of the body of the pancreas. Am Surg (2002) 0.90
An exploration of relative health stock in advanced cancer patients. Med Decis Making (2004) 0.90
Understanding of an aggregate probability statement by patients who are offered participation in Phase I clinical trials. Cancer (2005) 0.89
An Internet method to assess cancer patient information needs and enhance doctor-patient communication: a pilot study. J Cancer Educ (2007) 0.89
Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer. Radiother Oncol (2012) 0.88
Influence of delays to nonemergent colon cancer surgery on operative mortality, disease-specific survival and overall survival. Can J Surg (2009) 0.88
Value and cancer care: toward an equitable future. Clin Cancer Res (2010) 0.88
A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer (2012) 0.88
Induction cisplatin and paclitaxel followed by combination chemoradiotherapy with 5-fluorouracil, cisplatin, and paclitaxel before resection in localized esophageal cancer: a phase II report. Ann Surg Oncol (2006) 0.87
A multigene prognostic assay for selection of adjuvant chemotherapy in patients with T3, stage II colon cancer: impact on quality-adjusted life expectancy and costs. Value Health (2012) 0.87
Esophageal Cancer Clinical Practice Guidelines. J Natl Compr Canc Netw (2006) 0.87
Gastric cancer. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2003) 0.86
Colon carcinoma cells induce CXCL11-dependent migration of CXCR3-expressing cytotoxic T lymphocytes in organotypic culture. Cancer Immunol Immunother (2006) 0.86
Assessing compliance with national comprehensive cancer network guidelines for elderly patients with stage III colon cancer: the Fox Chase Cancer Center Partners' initiative. Clin Colorectal Cancer (2011) 0.86
Decision tree-based modeling of androgen pathway genes and prostate cancer risk. Cancer Epidemiol Biomarkers Prev (2011) 0.86
Influence of Diabetes on the Interpretation of PET Scans in Patients With Esophageal Cancer. Gastrointest Cancer Res (2009) 0.85
Knowledge, attitudes, and self-efficacy as predictors of preparedness for oncology clinical trials: a mediational model. Med Decis Making (2013) 0.85
Sequelae of axillary lymph node dissection in older women with stage 1 and 2 breast carcinoma. Cancer (2002) 0.85
Effects of a decision support intervention on decisional conflict associated with microsatellite instability testing. Cancer Epidemiol Biomarkers Prev (2011) 0.85
Decisional conflict among patients who accept or decline participation in phase I oncology studies. J Empir Res Hum Res Ethics (2008) 0.84
Development of new agents for the treatment of advanced colorectal cancer. Clin Colorectal Cancer (2003) 0.84
Barriers to participation in cancer prevention clinical trials. Acta Oncol (2010) 0.84
The impact of misclassification due to survey response fatigue on estimation and identifiability of treatment effects. Stat Med (2011) 0.83
Can molecular imaging predict response to preoperative chemoradiation in patients with rectal cancer? A Fox Chase Cancer Center prospective experience. Semin Oncol (2005) 0.83